• Something wrong with this record ?

Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia

R. Bezdekova, T. Jelinek, R. Kralova, M. Stork, P. Polackova, P. Vsianska, L. Brozova, J. Jarkovsky, M. Almasi, I. Boichuk, Z. Knechtova, M. Penka, L. Pour, S. Sevcikova, R. Hajek, L. Rihova

. 2021 ; 195 (1) : 95-107. [pub] 20210909

Language English Country Great Britain

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22003542

Plasma cell leukaemia (PCL) is a rare and very aggressive plasma cell disorder. Preventing a dismal outcome of PCL requires early diagnosis with appropriate analytical tools. Therefore, the investigation of 33 patients with primary and secondary PCL was done when the quantity of circulating plasma cells (PCs) using flow cytometry (FC) and morphology assessment was evaluated. The phenotypic profile of the PCs was also analysed to determine if there is an association with clinical outcomes and to evaluate the prognostic value of analysed markers. Our results revealed that FC is an excellent method for identifying circulating PCs as a significantly higher number was identified by FC than by morphology (26·7% vs. 13·5%, P = 0·02). None of secondary PCL cases expressed CD19 or CD20. A low level of expression with similar positivity of CD27, CD28, CD81 and CD117 was found in both PCL groups. A decrease of CD44 expression was detected only in secondary PCL. Expression of CD56 was present in more than half of PCL cases as well as cytoplasmic nestin. A decreased level of platelets, Eastern Cooperative Oncology Group score of 2-3 and lack of CD20+ PC were associated with a higher risk of death. FC could be incorporated in PCL diagnostics not only to determine the number of circulating PCs, but also to assess their phenotype profile and this information should be useful in patients' diagnosis and possible prognosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003542
003      
CZ-PrNML
005      
20220127150123.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17713 $2 doi
035    __
$a (PubMed)34500493
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Bezdekova, Renata $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia / $c R. Bezdekova, T. Jelinek, R. Kralova, M. Stork, P. Polackova, P. Vsianska, L. Brozova, J. Jarkovsky, M. Almasi, I. Boichuk, Z. Knechtova, M. Penka, L. Pour, S. Sevcikova, R. Hajek, L. Rihova
520    9_
$a Plasma cell leukaemia (PCL) is a rare and very aggressive plasma cell disorder. Preventing a dismal outcome of PCL requires early diagnosis with appropriate analytical tools. Therefore, the investigation of 33 patients with primary and secondary PCL was done when the quantity of circulating plasma cells (PCs) using flow cytometry (FC) and morphology assessment was evaluated. The phenotypic profile of the PCs was also analysed to determine if there is an association with clinical outcomes and to evaluate the prognostic value of analysed markers. Our results revealed that FC is an excellent method for identifying circulating PCs as a significantly higher number was identified by FC than by morphology (26·7% vs. 13·5%, P = 0·02). None of secondary PCL cases expressed CD19 or CD20. A low level of expression with similar positivity of CD27, CD28, CD81 and CD117 was found in both PCL groups. A decrease of CD44 expression was detected only in secondary PCL. Expression of CD56 was present in more than half of PCL cases as well as cytoplasmic nestin. A decreased level of platelets, Eastern Cooperative Oncology Group score of 2-3 and lack of CD20+ PC were associated with a higher risk of death. FC could be incorporated in PCL diagnostics not only to determine the number of circulating PCs, but also to assess their phenotype profile and this information should be useful in patients' diagnosis and possible prognosis.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a CD antigeny $x analýza $7 D015703
650    _2
$a antigeny nádorové $x analýza $7 D000951
650    12
$a krevní obraz $x metody $7 D001772
650    _2
$a kostní dřeň $x patologie $7 D001853
650    _2
$a buňky kostní dřeně $x chemie $7 D001854
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a falešně negativní reakce $7 D005188
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $x metody $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a plazmocelulární leukemie $x krev $x mortalita $7 D007952
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádorové cirkulující buňky $7 D009360
650    12
$a plazmatické buňky $x chemie $x ultrastruktura $7 D010950
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jelinek, Tomas $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Kralova, Romana $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Stork, Martin $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Polackova, Petra $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Vsianska, Pavla $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Brozova, Lucie $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Almasi, Martina $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Boichuk, Ivanna $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Knechtova, Zdenka $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Penka, Miroslav $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Pour, Ludek $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Sevcikova, Sabina $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Rihova, Lucie $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 195, č. 1 (2021), s. 95-107
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34500493 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150119 $b ABA008
999    __
$a ok $b bmc $g 1751104 $s 1154691
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 195 $c 1 $d 95-107 $e 20210909 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options